MNTA:NSD-Momenta Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 6.24B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. As of September 30, 2020, Momenta Pharmaceuticals, Inc. operates as a subsidiary of Johnson & Johnson.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD12.70B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Aphria Inc

N/A

USD4.12B 43.21 454.68
CRON Cronos Group Inc

N/A

USD3.82B 37.11 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.95B 23.15 65.69
TLRY Tilray, Inc

N/A

USD2.85B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.66B 14.79 14.06
ENDP Endo International plc

N/A

USD1.60B N/A 9.94
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.58B 12.42 7.71
ORGO Organogenesis Holdings Inc

N/A

USD1.35B 456.50 77.95

ETFs Containing MNTA

Symbol Name Weight Mer Price(Change) Market Cap
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

N/A

USD0.48B
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.10 %

N/A

USD2.87B
XSMO Invesco S&P SmallCap Mome.. 0.00 % 0.39 %

N/A

USD0.13B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

N/A

USD1.46B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

N/A

USD1.87B
IDP6:LSE iShares S&P SmallCap 600 .. 0.00 % 0.40 %

N/A

USD1.31B
ISP6:LSE iShares S&P SmallCap .. 0.00 % 0.40 %

N/A

USD0.77B
IUS3:F iShares S&P SmallCap .. 0.00 % 0.40 %

N/A

USD1.31B
IUS3:XETRA iShares S&P SmallCap .. 0.00 % 0.40 %

N/A

USD1.31B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.39% N/A N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.39% N/A N/A 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 80.18% N/A N/A 13% F
Risk Adjusted Return 55.37% N/A N/A 71% C-
Market Capitalization 6.24B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.79 N/A N/A N/A N/A
Price / Cash Flow Ratio -30.48 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -65.12% N/A N/A N/A N/A
Return on Assets -30.56% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.79 N/A N/A N/A N/A
Short Percent 7.57% N/A N/A N/A N/A
Beta 1.79 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.